Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis

Using oral topiramate for primary generalized and focal-to-bilateral tonic-clonic seizures in patients 2 years of age and older: a review of the literature

INTRODUCTION

Topiramate is a drug belonging to the second generation of antiseizure arsenal, used to treat focal onset seizures without generalization, focal-to-bilateral tonic-clonic seizures, and primary generalized tonic-clonic seizures.

AREAS COVERED

The narrative evaluation of topiramate's clinical research that has been published in this article focuses on the medication's effectiveness and safety when used to treat primary generalized and focal-to-bilateral tonic-clonic seizures. From their founding to the present, the databases MEDLINE, SCOPUS, EBSCO, and GOOGLE SCHOLAR were searched.

EXPERT OPINION

Topiramate treatment has the obvious benefit of being effective in treating tonic-clonic seizures; nevertheless, it may have a drawback in that up to 56% of patients discontinue therapy due to its rather poor tolerability, particularly at doses exceeding 600 mg daily. Patients are most bothered by psychiatric and cognitive side effects, and then by appetite and weight decrease. While the onset of anorexia cannot be prevented by changing the dosage regimen, psychiatric and cognitive side effects can be mitigated by slowly titrating the topiramate dose.

Potential causal link between dietary intake and epilepsy: a bidirectional and multivariable Mendelian randomization study

Background

Epilepsy is a common neurological disease, and dietary intake has been suggested as a potential modifiable risk factor. However, the causality of associations between dietary intake and epilepsy remains uncertain. This study aimed to investigate the potential causal relationships between various dietary intakes and epilepsy using Mendelian randomization (MR) analysis.

Methods

A two-sample MR approach was employed, utilizing genetic variants associated with dietary factors as instrumental variables (IVs). Genome-Wide Association Study (GWAS) summary data on dietary intakes were obtained from the UK Biobank, while data on epilepsy were sourced from the European Bioinformatics Institute. The number of genetic variants used as IVs varied for each dietary factor. Inverse-variance weighted (IVW), weighted median, MR-Egger, and Bayesian weighted MR (BWMR) methods were used to assess causality. Multivariable MR (MVMR) was performed, adjusting for potential confounders. Sensitivity analyses were conducted to evaluate the robustness of the findings.

Results

The study identified a significant inverse association between non-oily fish intake and epilepsy risk (OR = 0.281, 95% CI: 0.099-0.801, p = 0.018) using the IVW method. This finding was corroborated by the BWMR analysis (OR = 0.277, 95% CI: 0.094-0.814, p = 0.020). The MVMR analysis further confirmed the protective effect of non-oily fish intake on epilepsy risk after adjusting for potential confounders. In the reverse MR analysis, epilepsy was associated with reduced water intake (OR = 0.989, 95% CI: 0.980-0.997, p = 0.011).

Conclusion

The present MR study provides evidence of a causal, protective relationship between non-oily fish intake and reduced epilepsy risk. Additionally, the findings suggest that epilepsy may influence water intake patterns. These results contribute to our understanding of the role of dietary factors in epilepsy and may inform dietary recommendations for the management and prevention of this condition.

Inhibiting the IRAK4/NF-κB/NLRP3 signaling pathway can reduce pyroptosis in hippocampal neurons and seizure episodes in epilepsy

BACKGROUND

Interleukin-1 receptor-associated kinase 4 (IRAK4) plays an important role in immune modulation in various central nervous system disorders. However, IRAK4 has not been reported in epilepsy models in animal and clinical studies, nor has its involvement in regulating pyroptosis in epilepsy.

METHOD

First, we performed transcriptome sequencing, quantitative real-time polymerase chain reaction, and western blot analysis on the hippocampal tissues of refractory epilepsy patients to measure the mRNA and protein levels of IRAK4 and pyroptosis-related proteins. Second, we successfully established a pentylenetetrazol (PTZ)-induced seizure mouse model. We conducted behavioral tests, electroencephalography, virus injection, and molecular biology experiments to investigate the role of IRAK4 in seizure activity regulation.

RESULTS

IRAK4 is upregulated in the hippocampus of epilepsy patients and PTZ-induced seizure model mice. IRAK4 expression is observed in the hilar neurons of PTZ-induced mice. Knocking down IRAK4 in PTZ-induced mice downregulated pyroptosis-related protein expression and alleviated seizure activity. Overexpressing IRAK4 in naive mice upregulated pyroptosis-related protein expression and increased PTZ-induced abnormal neuronal discharges. IRAK4 and NF-κB were found to bind to each other in patient hippocampal tissue samples. Pyrrolidine dithiocarbamate reversed the pyroptosis-related protein expression increase caused by PTZ. PF-06650833 alleviated seizure activity and inhibited pyroptosis in PTZ-induced seizure mice.

CONCLUSION

IRAK4 plays a key role in the pathological process of epilepsy, and its potential mechanism may be related to pyroptosis mediated by the NF-κB/NLRP3 signaling pathway. PF-06650833 has potential as a therapeutic agent for alleviating epilepsy.

Risk assessment of arrhythmias related to three antiseizure medications: a systematic review and single-arm meta-analysis

Objective

Antiseizure medications (ASMs) are first line therapy for seizure disorders. Their effects on arrhythmias, especially the risk of arrhythmias associated with lacosamide (LCM), levetiracetam (LEV), and perampanel (PER), have been intensely investigated.

Methods

We searched four databases (PubMed, EMBASE, Cochrane Library, and Web of Science) until August 6, 2023. We used a common effects model and reported data as pooled incidence with 95% CIs. Meta-analyses were conducted to elucidate the risk of arrhythmias with different drugs, and Egger's regression was performed to detect publication bias analysis.

Results

We included 11 clinical trials with 1,031 participants. The pooled incidence of arrhythmias in the LEV group was 0.005 (95% CI: 0.001-0.013), while it was 0.014 in the LCM group (95% CI: 0.003-0.030). Publication bias analyses indicated no significant bias in the LEV group (t = 0.02, df = 4, p-value = 0.9852) but a significant bias in the LCM group (t = 5.94, df = 3, p-value = 0.0095). We corrected for this bias in the LCM group using the trim-and-fill method, which yielded a similar pooled incidence of 0.0137 (95% CI: 0.0036-0.0280), indicating good reliability. Due to insufficient studies, we could not conduct a meta-analysis for PER, and we analyzed them in our systematic review.

Conclusion

The use of LCM significantly elevated the risk of arrhythmias, while LEV had non-significant arrhythmogenic effects. As for the arrhythmogenic effects of PER, more clinical trials are needed in the future.